BioRad Laboratories (BIO)
(Delayed Data from NYSE)
$284.60 USD
+42.65 (17.63%)
Updated Aug 1, 2025 03:59 PM ET
After-Market: $285.16 +0.56 (0.20%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth D Momentum F VGM
Key Expected Earnings Data
Report Date | Period Ending | Zacks Consensus Estimate | Earnings ESP |
---|---|---|---|
10/29/2025
Time: -- |
9/2025 | $2.20 | 0.00% |
Earnings Summary
For their last quarter, BioRad Laboratories (BIO) reported earnings of $2.61 per share, beating the Zacks Consensus Estimate of $1.93 per share. This reflects a positive earnings surprise of 35.23%. Look out for BIO's next earnings release expected on October 29, 2025. For the next earning release, we expect the company to report earnings of $2.20 per share, reflecting a year-over-year increase of 9.45%.
Earnings History
Price & Consensus
Zacks News for BIO
Bio-Rad Stock Climbs Following the Launch of Four ddPCR Platforms
BIO: What are Zacks experts saying now?
Zacks Private Portfolio Services
New Strong Sell Stocks for July 10th
Hologic's Margin Stability Amid Tariffs: What's Behind the Confidence?
Investing in Bio-Rad (BIO)? Don't Miss Assessing Its International Revenue Trends
BIO FAQs
Bio-Rad Laboratories, Inc. (BIO) has announced they will report their next quarter earnings on October 29, 2025. For the next earning release, we expect the company to report earnings of $2.20 per share, reflecting a year-over-year increase of 9.45%.
Bio-Rad Laboratories, Inc. has announced they will report their previous quarter earnings after the close of the market on October 29, 2025.
The Zacks Consensus Estimate for Bio-Rad Laboratories, Inc. (BIO) for the quarter ending September 2025 is $2.20 a share. We expect Bio-Rad Laboratories, Inc. (BIO) to report earnings in line with the consensus estimate of $2.20 per share
In the earnings report for the quarter ending in September 2024, Bio-Rad Laboratories, Inc. (BIO) announced earnings of $2.01 per share versus the Zacks Consensus Estimate of $1.28 per share, representing a surprise of 57.03%.